



For Immediate Release

October 22, 2014

Contact: Lacey Washburn
Howell Marketing Strategies
lacey@howell-marketing.com
901-521-1453

DIGITAL PATHOLOGY ADVANCEMENTS AT TRUMBULL LABORATORIES, LLC

MEMPHIS, TN- The physicians of Pathology Group of the MidSouth announce today an advancement in lab technology with the installation of the Ventana iScan Coreo, a digital pathology whole slide scanner at Trumbull Laboratories, LLC.

A technology made available by Ventana Medical Systems, Inc., a member of Roche Tissue Diagnostics, the Ventana iScan Coreo provides advanced image quality for improved diagnostics and prognosis. Equipped with high speed brightfield slide scanning, the iScan Coreo slide scanner provides advancements including improvements to lab efficiency, pathologists productivity and diagnostic quality; anywhere/anytime access to digital cases and images; telepathology and case sharing; image analysis, proficiency testing and academic case sharing; and integrated patient reporting.

Paired with Virtuoso digital pathology software, iScan Coreo provides pathologists with a complete digital pathology solution from image acquisition through customized reporting, increasing operational efficiencies and productivity in the lab.

In response to a growing demand for digital pathology and personalized medicine in clinical practice, Trumbull Labs has installed the iScan Coreo scanner with hopes of enhancing the practice of pathology. The primary use of the iScan Coreo at Trumbull Labs will be to optimize workflow and provide the ability to scan multiple breast cases per day. The scanner auto detects a tissue specimen placed on the slide, adds focus points and scans the specimen.

The iScan Coreo will replace existing scan for positive breast biopsies and will provide an extra layer of safety for the patients. Trumbull Labs is the first laboratory to implement this technology in the Memphis and MidSouth area.

“This technology is now nationally recognized as the Gold Standard of modern analytical immunohistochemistry, and our use of it will allow Oncologists more precisely to tailor the very most effective treatment regimen for each breast cancer patient to afford her the most ‘clinically meaningful’ treatment,” said Thomas McC. Chesney, M.D., President of Pathology Group of the MidSouth. “By predicting which drugs will be effective or ineffective in a given case allows for truly ‘personalized medicine’ for each patient, and the highest standard of care.”

Roche Tissue Diagnostics is the largest company in the anatomic pathology industry today offering an FDA-cleared testing package of five key breast biomarkers with their corresponding image analysis algorithms and digital read applications for cancer patients. All IHC breast markers in the Ventana portfolio have both image analysis and digital read application FDA 510(k) and CE IVD clearances.

A ribbon cutting ceremony was held on Tuesday, September 30th at Trumbull Labs with representative in attendance from Roche Tissue Diagnostics.

About Trumbull Laboratories, LLC

The laboratory proudly carries the name of Merlin Trumbull, MD, a pioneer in diagnostic medicine. In 1947, Dr. Trumbull moved to Memphis and quickly developed a sterling reputation for his excellent diagnostic and interpretive skills. This reputation enabled him to attract outstanding pathologists and build the practice known today as Pathology Group of the MidSouth.

With this rich legacy, the PGM/Trumbull team has been able to customize courier pick-up; enhance pathology reports; reduce turn-around-time for results; employ the very best technologists, technicians and support personnel; invest in state-of-the-art technology and instrumentation; support clients with dedicated Client Services and Sales representatives; and ultimately raise the standard for anatomic laboratory services in the MidSouth. For more information, please visit www.trumbulllabs.com.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

About Ventana

Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the RocheGroup, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA products are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to help reduce errors, support diagnosis and enable informed treatment decisions by anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies.